Management of localized prostate cancer.

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64

Natural history of early, localized prostate cancer. JAMA (2004) 7.44

Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA (1997) 3.80

The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Williston Park) (1997) 1.07

Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25

Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67

Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology (2005) 1.37

Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials (2003) 1.33

High-grade prostatic intraepithelial neoplasia. Rev Urol (2004) 1.18

Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin (2014) 1.10

Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA. BJU Int (2004) 1.04

Attitudes and use of complementary medicine in men with prostate cancer. J Urol (2002) 1.02

Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. Rev Urol (2002) 0.96

Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol (2005) 0.90

Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin (2013) 0.88

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol (2011) 0.87

Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol (2002) 0.85

Hormonal therapy for prostate cancer. Rev Urol (2006) 0.85

Prostatic intraepithelial neoplasia: an overview. Rev Urol (2005) 0.85

Testosterone replacement in men with andropause: an overview. Rev Urol (2004) 0.84

Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology (2002) 0.83

A neurocomputational model for prostate carcinoma detection. Cancer (2003) 0.83

Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. Rev Urol (2003) 0.82

Chemoprevention strategies in the prostate: an overview. Rev Urol (2002) 0.81

Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer. Rev Urol (2003) 0.79

Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. Urology (2003) 0.78

Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer. Rev Urol (2004) 0.78

Early diagnosis and staging of prostate cancer. Rev Urol (2003) 0.77

Best of the 2012 AUA Annual Meeting: Highlights From the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA. Rev Urol (2012) 0.75

Best of the AUA Annual Meeting: Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA. Rev Urol (2010) 0.75

Challenges with luteinizing hormone-releasing hormone agonists: flare and surge. Rev Urol (2004) 0.75

Urology Update from Jackson Hole: Highlights from the 3rd Annual Jackson Hole Summer Urologic Conference July 28-August 3, 2001, Jackson Hole, WY. Rev Urol (2002) 0.75

Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA. Rev Urol (2013) 0.75

Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy. Rev Urol (2002) 0.75

Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? Urology (2002) 0.75

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology (2002) 0.75

Testosterone replacement therapy for a man with prostate cancer. Rev Urol (2004) 0.75